TEST DIRECTORY

AND OR

TOP
drug test
immunosuppressive drug

Laboratory：Hachioji

○immunosuppressive drug

TEST NAME	SPECIMEN REQUIREMENT （ｍL）	CONTAINER	CAP COLOR	STORE TEMPERATURE (STABILITY)	TURNAROUND TIME (DAY)	METHODOLOGY	REFERENCE RANGE (UNIT)	BLOOD COLLECTION TIME
Cyclosporine	whole blood (with EDTA-2K) 0.7	PKF			2-4	ECLIA Electro chemiluminescence immunoassay (ECLIA) Antibody-bound beads are reacted with antigens that are secondarily reacted with antibodies labeled with rutheniumpyridine complexes, which promotes the electrochemical reaction. The emission intensity of ruthenium-pyridine complexes is measured.	(ng/mL)	Immediately before the next administration(Trough concentration)
Tacrolimus	whole blood (with EDTA-2K) 0.7	PKF			2-4	ECLIA Electro chemiluminescence immunoassay (ECLIA) Antibody-bound beads are reacted with antigens that are secondarily reacted with antibodies labeled with rutheniumpyridine complexes, which promotes the electrochemical reaction. The emission intensity of ruthenium-pyridine complexes is measured.	(ng/mL)	Immediately before the next administration(Trough concentration)
Everolimus	whole blood (with EDTA-2K) 1.0	PKF			2-4	ECLIA Electro chemiluminescence immunoassay (ECLIA) Antibody-bound beads are reacted with antigens that are secondarily reacted with antibodies labeled with rutheniumpyridine complexes, which promotes the electrochemical reaction. The emission intensity of ruthenium-pyridine complexes is measured.	When used as an immunosuppressive drug with cyclosporine Trough: 3.0-8 When used as an anti-malignant tumor drug Trough: 5-15 (ng/mL)	Immediately before the next administration(Trough concentration)
Mycophenolic acid	plasma 0.5	PN2,PN5 ↓ A00		（7 days）	2-5	EIA Enzyme immunoassay (EIA) EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.	(μg/mL)